pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Sanofi ($SNY) · news · pharmadog
← back to Sanofi
News mentioning $SNY
309
stories
13h
ICE detention of Princeton scientist rattles academia
stat
18h
STAT+: Up and down the ladder: The latest comings and goings
stat
19h
An Insmed takeout by Sanofi would be ‘clear strategic fit’ in respiratory space
biospace
20h
STAT+: Pharmalittle: We’re reading about Sanofi eyeing Insmed, AI speeding drug development, and more
stat
20h
STAT+: Early results for Alterome’s KRAS drug for pancreas, lung and colon cancer arrive
stat
21h
Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff
biopharma dive
1d
Sanofi's Infilbray wins first approval for neurological symptoms of Gaucher
endpoints
1d
Sanofi gains FDA clearance for Gaucher disease pill
biopharma dive
1d
Sanofi considering a deal to acquire Insmed, according to report
endpoints
1d
Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic disease
biospace
1d
STAT+: Pharmalittle: We’re reading about a Merck AI deal, China and the pharma supply chain, and more
stat
2d
FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease
fda press
3d
5 acquisitions that forced Big Pharmas to co-parent
biospace
4d
Their loss, our gain? Canada makes its case to Europe amid U.S. instability
biospace
5d
STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
stat
5d
Seawolf surfaces with $100M, $1.2B Sanofi pact for redosable DNA medicines
biospace
5d
Big-name investors pour $100M into DNA therapeutics developer Seawolf
biopharma dive
5d
Aclaris drops TSLP program from pipeline after flunking phase 2 eczema test
fiercebiotech
5d
Flagship commits £100M to set up AI-focused biotech incubation outpost in London
fiercebiotech
7d
Windward Bio hits Nasdaq with $175M IPO, plus another $50M from Sanofi
endpoints
7d
Windward nets $175M IPO, bringing 2026 biotech debuts to 35
biospace
7d
Regeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trial
biospace
8d
Sanofi-backed Windward hits $225M IPO goal, as Rezera delays listing over ‘market conditions’
fiercebiotech
8d
Windward prices $175M IPO to advance China-licensed lung drugs
biopharma dive
8d
Big Pharma-backed Seawolf surfaces with $100M to hand, $1.2B Sanofi DNA med pact
fiercebiotech
8d
Blackstone bets $1.5B on Pfizer’s obesity drug
biopharma dive
9d
10 companies hiring in New Jersey
biospace
11d
AstraZeneca buys partner Omniose for bacterial vaccine technology
fiercebiotech
11d
AbCellera becomes latest biotech to abandon dream of developing OX40 drug
fiercebiotech
11d
BioSpace 2027 Best Places to Work shines light on most admired employers
biospace
← prev
page 1 of 11
next →